Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Relugolix Approved in Europe for Prostate Cancer
May 9, 2022
- Hatsuo Aoki, Former Astellas Chair and JPMA President, Dies at 86
April 28, 2022
- Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
- Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
April 28, 2022
- PharmaEssentia Submits Its 1st Drug in Japan for Polycythemia Vera
April 28, 2022
- J-TEC Files Autologous Cultured Epidermis for Stable Vitiligo; Launch Eyed in FY2023
April 28, 2022
- Enhertu Scores 5th Breakthrough Therapy Tag, This Time for HER2 Low Breast Cancer
April 28, 2022
- Kissei Files Fostamatinib, Orphan Drug for ITP, in Japan
April 28, 2022
- JCR Taps Ex-GSK Japan Chief Philippe Fauchet as Board Director
April 28, 2022
- CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
April 28, 2022
- Pfizer’s Once-Weekly Short Stature Treatment Ngenla Now Available in Japan
April 28, 2022
- Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
April 27, 2022
- Otsuka Grabs Japan Sales Rights to Cognitive Function Testing App
April 27, 2022
- Fuso Gets Japan Rights to Heart Failure Drug from Tokyo Upstart
April 27, 2022
- Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement
April 26, 2022
- Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
April 26, 2022
- EU Panel Confirms Nod for Kissei-Originated Fibroid Drug
April 26, 2022
- Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
- Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…